ESR1 and breast cancer: Our data showed that SET overexpression enhanced ERE-mediated ER activity (Figure 4D), suggesting that SET could possibly interfere with the ER signaling pathways and contribute to tamoxifen resistance in breast cancer, at least, in part, via the inhibition of PP2A activity.